|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hsu HC, Huang AM, Lai PL, et al: Genetic
alterations at the splice junction of p53 gene in human
hepatocellular carcinoma. Hepatology. 19:122–128. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hsu HC, Jeng YM, Mao TL, et al: β-catenin
mutations are associated with a subset of low-stage hepatocellular
carcinoma negative for hepatitis B virus and with favorable
prognosis. Am J Pathol. 157:763–770. 2000.
|
|
4
|
Yuan JM, Govindarajan S, Ross RK, et al:
Chronic infection with hepatitis G virus in relation to
hepatocellular carcinoma among non-Asians in Los Angeles County,
California. Cancer. 86:936–943. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kagan HM and Trackman PC: Properties and
function of lysyl oxidase. Am J Respir Cell Mol Biol. 5:206–210.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim YM, Kim EC and Kim Y: The human lysyl
oxidase-like 2 protein functions as an amine oxidase toward
collagen and elastin. Mol Biol Rep. 38:145–149. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bais MV, Nugent MA, Stephens DN, et al:
Recombinant lysyl oxidase propeptide protein inhibits growth and
promotes apoptosis of pre-existing murine breast cancer xenografts.
PLoS One. 7:e311882012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Palamakumbura AH, Vora SR, Nugent MA, et
al: Lysyl oxidase propeptide inhibits prostate cancer cell growth
by mechanisms that target FGF-2-cell binding and signaling.
Oncogene. 28:3390–3400. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hurtado PA, Vora S, Sume SS, et al: Lysyl
oxidase propeptide inhibits smooth muscle cell signaling and
proliferation. Biochem Biophys Res Commun. 366:156–161. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Min C, Kirsch KH, Zhao Y, et al: The tumor
suppressor activity of the lysyl oxidase propeptide reverses the
invasive phenotype of Her-2/neu-driven breast cancer. Cancer Res.
67:1105–1112. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Palamakumbura AH, Jeay S, Guo Y, et al:
The propeptide domain of lysyl oxidase induces phenotypic reversion
of ras-transformed cells. J Biol Chem. 279:40593–40600. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Min C, Zhao Y, Romagnoli M, et al: Lysyl
oxidase propeptide sensitizes pancreatic and breast cancer cells to
doxorubicin-induced apoptosis. J Cell Biochem. 111:1160–1168. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barker HE, Cox TR and Erler JT: The
rationale for targeting the LOX family in cancer. Nat Rev Cancer.
12:540–552. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Edmondson HA and Steiner PE: Primary
carcinoma of the liver: a study of 100 cases among 48,900
necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang YH, Chen K, Li B, et al: Estradiol
inhibits osteoblast apoptosis via promotion of autophagy through
the ER-ERK-mTOR pathway. Apoptosis. 18:1363–1375. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chiu CC, Lin CH and Fang K: Etoposide
(VP-16) sensitizes p53-deficient human non-small cell lung cancer
cells to caspase-7-mediated apoptosis. Apoptosis. 10:643–650. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Novello C, Pazzaglia L, Cingolani C, et
al: miRNA expression profile in human osteosarcoma: Role of miR-1
and miR-133b in proliferation and cell cycle control. Int J Oncol.
42:667–675. 2013.PubMed/NCBI
|
|
18
|
Aigelsreiter A, Ress AL, Bettermann K, et
al: Low expression of the putative tumour suppressor spinophilin is
associated with higher proliferative activity and poor prognosis in
patients with hepatocellular carcinoma. Br J Cancer. 108:1830–1837.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li B, Yang Y, Jiang S, et al:
Adenovirus-mediated overexpression of BMP-9 inhibits human
osteosarcoma cell growth and migration through downregulation of
the PI3K/AKT pathway. Int J Oncol. 41:1809–1819. 2012.PubMed/NCBI
|
|
20
|
Liu ZL, Wang G, Peng AF, et al: Fatty acid
synthase expression in osteosarcoma and its correlation with
pulmonary metastasis. Oncol Lett. 4:878–882. 2012.PubMed/NCBI
|
|
21
|
Thompson L, Wang S, Tawfik O, et al:
Effect of 25-hydroxyvitamin D3 and 1 α,25
dihydroxyvitamin D3 on differentiation and apoptosis of
human osteosarcoma cell lines. J Orthop Res. 30:831–844. 2012.
|
|
22
|
Kamei S, Sakayama K, Tamashiro S, et al:
Ketoprofen in topical formulation decreases the matrix
metalloproteinase-2 expression and pulmonary metastatic incidence
in nude mice with osteosarcoma. J Orthop Res. 27:909–915. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Korpi JT, Hagstrom J, Lehtonen N, et al:
Expression of matrix metalloproteinases-2, −8, −13, −26, and tissue
inhibitors of metalloproteinase-1 in human osteosarcoma. Surg
Oncol. 20:e18–22. 2011.
|
|
24
|
Zhang Y, Song L, Cai L, et al: Effects of
baicalein on apoptosis, cell cycle arrest, migration and invasion
of osteosarcoma cells. Food Chem Toxicol. 53C:325–333.
2012.PubMed/NCBI
|
|
25
|
Gu X, Xing L, Shi G, et al: The circadian
mutation PER2S662G is linked to cell cycle
progression and tumorigenesis. Cell Death Differ. 19:397–405.
2012.
|
|
26
|
Oka K, Ohya-Shimada W, Mizuno S, et al:
Up-regulation of cyclin-E1 via proline-mTOR pathway is
responsible for HGF-mediated G1/S progression in the
primary culture of rat hepatocytes. Biochem Biophys Res Commun.
435:120–125. 2013.PubMed/NCBI
|
|
27
|
Rasmussen N and Rathmell WK: Looking
beyond inhibition of VEGF/mTOR: emerging targets for renal cell
carcinoma drug development. Curr Clin Pharmacol. 6:199–206. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Van Waes C: Nuclear factor-κB in
development, prevention, and therapy of cancer. Clin Cancer Res.
13:1076–1082. 2007.
|
|
29
|
Peng L, Liu A, Shen Y, et al: Antitumor
and anti-angiogenesis effects of thymoquinone on osteosarcoma
through the NF-κB pathway. Oncol Rep. 29:571–578. 2013.PubMed/NCBI
|
|
30
|
Jeng YM, Chang CC, Hu FC, et al:
RNA-binding protein insulin-like growth factor II mRNA-binding
protein 3 expression promotes tumor invasion and predicts early
recurrence and poor prognosis in hepatocellular carcinoma.
Hepatology. 48:1118–1127. 2008. View Article : Google Scholar
|
|
31
|
Chen YL, Wang TH, Hsu HC, et al:
Overexpression of CTHRC1 in hepatocellular carcinoma promotes tumor
invasion and predicts poor prognosis. PLoS One. 8:e703242013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sanchez-Morgan N, Kirsch KH, Trackman PC,
et al: The lysyl oxidase propeptide interacts with the
receptor-type protein tyrosine phosphatase kappa and inhibits
β-catenin transcriptional activity in lung cancer cells. Mol Cell
Biol. 31:3286–3297. 2011.PubMed/NCBI
|
|
33
|
Yoon JH, Park JK, Kang YH, et al: Lysyl
oxidase G473A polymorphism is closely associated with
susceptibility to gastric cancer in a South Korean population.
APMIS. 119:762–768. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yu Z, Sato S, Trackman PC, et al: Blimp1
activation by AP-1 in human lung cancer cells promotes a migratory
phenotype and is inhibited by the lysyl oxidase propeptide. PLoS
One. 7:e332872012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Barcellos-Hoff MH and Ravani SA:
Irradiated mammary gland stroma promotes the expression of
tumorigenic potential by unirradiated epithelial cells. Cancer Res.
60:1254–1260. 2000.PubMed/NCBI
|
|
36
|
Wiseman BS and Werb Z: Stromal effects on
mammary gland development and breast cancer. Science.
296:1046–1049. 2002. View Article : Google Scholar : PubMed/NCBI
|
